Alexander Cohen: How Long Should You Treat VTE?
Alexander Cohen, Consultant Physician at Guy’s and St Thomas’ NHS Foundation Trust, shared a post on LinkedIn:
“How long should you treat venous thromboembolism (VTE)?
Not simply 3–6 months or indefinitely.
The real challenge is balancing the risks of recurrent clots and bleeding.
Our two new JTH papers provide complementary dynamic risk prediction tools for recurrences and bleeding to support personalised treatment decisions throughout the VTE journey.”
Title: A novel dynamic risk score to predict venous thromboembolism recurrences after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancer
Authors: Alexander T. Cohen, Satarupa Choudhuri, Imran Khan, Kevin G. Pollock, Mikel Bober-Irizar, Zbigniew Galias, Amaia Irizar, Miroslaw Bober

Read the Full Article on JTH
Title: A novel dynamic risk score to predict clinically significant bleeding after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancer
Authors: Satarupa Choudhuri, Alexander T. Cohen, Imran Khan, Kevin G. Pollock, Mikel Bober-Irizar, Zbigniew Galias, Amaia Irizar, Miroslaw Bober

Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 20, 2026, 19:17Michael Braun: The Work Is Not Finished in Sickle Cell Disease
-
Jun 20, 2026, 19:11Ayesha Masood: Delighted to Share My First Published Meta-Analysis
-
Jun 20, 2026, 18:56Registration Closing Tonight – 3rd Antithrombotic Stewardship Summit at ISTH 2026 – Anticoagulation Forum
-
Jun 20, 2026, 13:06Bastian Volbers: ESO and SESAM Sign Landmark Affiliation Agreement at SESAM 2026
-
Jun 20, 2026, 12:56Yusra Junaid: Two New Publications in Thrombosis and Cancer Research
-
Jun 20, 2026, 12:39Mayka Sanchez: Updates from EFAPH 2026 Meeting
-
Jun 20, 2026, 12:22Karen Fahey: A More Inclusive Future for the Bleeding Disorders Community
-
Jun 20, 2026, 10:48Alliah Czarielle Formalejo: Loving People Without Defining Them
-
Jun 20, 2026, 10:18Luciano Martelotto: CD200R1, IL-17A, and the Future of Cancer Thrombosis Prevention